


The DrugMatrix® Database

Scott S Auerbach, Ph.D., D.A.B.T. National Toxicology Program at NIEHS

CHE Conference Call

13 December 2012







Disclaimer

The statements, opinions or conclusions contained herein do not necessarily represent the statements, opinions or conclusions of NTP, NIEHS, NIH or the United States government.




Outline

- Part 1: Overview of DM
- Part 2: Example Application of DM in a Short-term Toxicity Assessments



Part 1: Overview of DrugMatrix





DrugMatrix

- DrugMatrix
 - Large-scale Rat Toxicogenomics Database and Analysis Tool
 - https://ntp.niehs.nih.gov/drugmatrix/index.html
- Originally owned by Iconix Pharmaceuticals and Entelos, Inc.
 - No data for these resources were generated by NTP
- Acquired by NTP in late 2010






Goals of Acquisition

- Make the computational and data resources <u>open to the public</u> (no fee)
- Facilitate the integration of toxicogenomics into hazard characterization
- **Build a bridge** between traditional toxicology and Tox21




DrugMatrix Database Content

- ~ 700 Short-term toxicity studies (0.25 to 5 days) in male SD rats
- ~ 637 compounds studied at multiple doses, time points and tissues
- ~ 5600 drug-treatment transcript profiles
- ~ 13,000 Codelink RU1 Microarrays
- ~ 5,000 Affymetrix RG230-2 Arrays
- ~ 127,000 histopathology measurements
- ~ 150 histopathology diagnoses over 7 tissues
- ~ 100,000 hematology and chemistry measurements
- ~ 138 hand annotated pathways
- ~ 290 scorable genomic signatures
- ~ 2500 pathway-based scorable signatures
- ~ 130 in vitro assays
- ~ 900 chemicals with detailed literature curation
- ~ 8000 chemical structures
- ~ 60,000 literature facts
- ~ 123,000 frozen samples





DrugMatrix Chemical Diversity





DrugMatrix Data Download DrugMatrix Array Data

- <a>ftp://anonftp.niehs.nih.gov/drugmatrix
- Unprocessed microarray data
- Microarray data normalized by organ
- Individual animal toxicology data
- In vitro screening data
- Chemical Annotations



DrugMatrix Functionality and Analysis Tools

- Upload your own data for analysis or mine the DrugMatrix data
 - Data you upload is private not shared with the government or other users
- Contextualize your data relative to over 4000 expression profiles elicited by >600 well characterized, phenotypically anchored prototype agents
- Find similar expression profiles
- Determine significantly up and down regulated genes
- Perform gene ontology analysis of perturbed genes
- Visualize expression profiles on pathways
- Score expression profiles for >50 phenotypes with genomic signatures
- Construct expression patterns for putative biomarker sets
- Test the performance of biomarker sets for detecting phenotypes
- Find consistently changed genes
- Identify enriched literature annotations in groups of expression profiles
- Mine the literature




Part 2: Example Application of DrugMatrix

Toxicogenomic Assessment of DE-71 (Study Scientist: Dr. June Dunnick)



DE-71: A mixture of polybrominated diphenyl ethers



- PBDEs are flame retardant components that bioaccumulate; persistent organic pollutants
- Widespread human exposure



Gene Expression Study design

- Dose level: 0 or 50 mg/kg/day
- Route: Oral Gavage (corn oil)
- Model: Male Wistar Han rats
- Exposure period: gestational day (GD) 6 to postnatal day (PND)
 21
- Euthanized: PND 22
- Tissue evaluated: Liver
- Question: What are the potential toxicological effects of DE-71 that can be identified by toxicogenomics?
- DE-71 expression studies are not included in DrugMatrix
 Database



DrugMatrix Analysis of DE-71- Top DEGs (Liver)

- Cyp1a1, Cyp2b, Cyp2c

- Fgf21, Cyp17a1, Abcg8

Induced

Repressed

| SIMILAR INDUCED REPRESSED DENDROGRAM OLIN. PATH. MOTIF SPLP TRANK | HISTOPAT | HOLOGY | SIMILAR INDUCED REPRESSED DENDROGRAM CLIN. PATH. MOTIF SPLP | TRANK HISTOPATHOLOGY |
|---|-------------|--|---|-------------------------------|
|)I MENU TRANSCRIPTIONAL RESPONSES (INDUCED) | | HENU TRANSCRIPTIONAL RESPONSES (REPRESSED) | | |
| GENE | CONFIDENCE | INTERVAL P VALUE | GENE | CONFIDENCE INTERVAL P VALUE |
| urinary protein 2 (1370396 x at,rc AA945585 at) | | 2.68E-10 | hypothetical protein FLJ32871 (DBSS) (1394309 at) | 6.62E-11 |
| urinary protein 2 (1370349 a at) | <u> </u> | 1.41E-10 | ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransfer | 3.68E-5 |
| estrogen sulfotransferase (1368733 at,M86758 at,NM 012883 PROBE1) | | 9.59E-8 | protein phosphatase 2 (formerly 2A), regulatory subunit B (PR 52), beta is | 3.61E-6 |
| cytochrome P450, family 2, subfamily A, polypeptide 3a (1369136 at) | <u> </u> | 1.07E-10 | CDNA clone IMAGE:7460165 (1371298 at) | 5.89E-11 |
| Iransmembrane protein 27 (1387013 at,NM 020976 PROBE1) | <u> </u> | 3.49E-9 | olfactory receptor 1696 (1370741 at) | 8.72E-5 |
| CEA-related cell adhesion molecule 10 (Non-specific probe) (1370371 a at) | <u></u> | 1.78E-11 | ✓ fibroblast growth factor 21 (1387643 at) | 3.48E-6 |
| urinary protein 2 (1389270 x at) | <u></u> | ▶ 1.87E-5 | N-terminal aceyltransferase 1 (DBSS) (1381204 at) | 6.13E-5 |
| vtochrome P450, family 2, subfamily c, polypeptide 29 (DBSS_moderate) (139615 | | 0.00E0 | ESTs (1392613 at) | 9.46E-6 |
| Kruppel-like factor 2 (lung) (DBSS) (1386040 at) | | 1.11E-12 | ESTs (1379156 at) | 2.07E-5 |
| CLIP associating protein 2 (1396604 at) | | 1.50E-7 | nuclear factor, erythroid derived 2 (1375040 at, BF397726 PROBE1) | 2.09E-6 |
| Iroquois related homeobox 2 (Drosophila) (1391457 a at) | | ▶ 1.30E-9 | Iow-density lipoprotein receptor-related protein 10 (Non-specific probe) (1 | 1.45E-6 |
| cytochrome P450, family 1, subfamily a, polypeptide 1 (1370269 at) | | 1.63E-6 | F-box protein FBL2 (DBSS) (1381961 at) | 1.06E-2 |
| cvtochrome P450 2c13 (1370495 s at,M82855cds s at) | | 7.54E-6 | Transcribed locus (1381317 at) | 5.61E-3 |
| RT1 class I, CE10 (1388202 at) | · · · · · · | 1.14E-4 | cytochrome P450, family 17, subfamily a, polypeptide 1 (1387123 at,M21 | 1.77E-7 |
| Cytochrome P450 2C24 (CYPIIC24) (P450-PROS2) (DBSS) (1370241 at,M18335 f | | 1.14E-9 | sorting nexin associated golgi protein 1 (DBSS) (1390064 at) | 2.18E-3 |
| ESTs (1397343 at) | <u> </u> | 8.82E-8 | Transcribed locus (1380306 at) | 3.14E-5 |
| Transcribed locus (1380543 at) | <u> </u> | 7.32E-10 | alpha-2-macroglobulin (1367794 at, J02635 PROBE1) | 4.14E-6 |
| cytochrome P450, family 2, subfamily b, polypeptide 13 (1387993 at) | · · · · · · | 2.69E-8 | ATP-binding cassette, sub-family G (WHITE), member 8 (1369440 at) | 3.65E-5 |
| Ieptin (1387748 at) | | 9.76E-8 | hypothetical protein MGC35130 (DBSS) (1386132 at) | 2.10E-4 |
| MGC14161 protein (DBSS) (1396720 at) | []. | 1.50E-7 | ESTs (1374610 at,AI599365 PROBE1) | 2.59E-4 |



DrugMatrix Analysis of DE-71- Signature Scoring


DE71_21.0D_50.0MG/KG_LIVER

TRANSCR. RESP.

| SIMILAR INDUCED REPRESSED DENDROGRAM CLIN. PATH. MOTIF SPLP TRAN | HISTOPATH | OLOGY | | |
|--|-----------|-------------|-----------|------------|
| HENU DRUG CLASSIFIER | | | | |
| SIGNATURE NAME | SP SCORE | POSTERIOR | LOGIT | DERIVATION |
| Hepatic hypertrophy, centrilobular LIVER RG230-2 ASPLP ToxFX.1.2.4 | 2.668 | 0.999835654 | 6.9067547 | RG230-2 |
| Hepatic lipid accumulation, centrilobular LIVER RG230-2 SPLP ToxFX.1.2.4 | 0.93 | 0.902890876 | 2.2297663 | RG230-2 |
| Hepatic lipid accumulation, macrovesicular LIVER RG230-2 ASPLP ToxFX.1.2.4 | 0.482 | 0.873777575 | 1.9347802 | RG230-2 |
| Hepatic lipid accumulation, periportal LIVER RG230-2 SPLP ToxFX.1.2.4 | 0.192 | 0.776136029 | 1.2432892 | RG230-2 |
| Hepatomegaly LIVER RG230-2 ASPLP ToxFX.1.2.4 | 0.292 | 0.775934833 | 1.2421316 | RG230-2 |

Rat Liver - Oil Red O

Dunnick, et al, Tox. Path., 2012



Vehicle

DE71





DrugMatrix Analysis of DE-71- Chemical Enrichment Analysis


• Chemical ontology enrichment analysis of the top 25 most similar expression studies (Hypergeometric Analysis)

| | А | В | С |
|----|--------------------|---|----------|
| 1 | CATEGORY | TERM | PVALUE |
| 2 | MECH_LEVEL_3 | aromatase 苯 | 4.17E-06 |
| 3 | MECH_LEVEL_2 | Inhibit estrogen biosynthesis 粩 | 4.44E-06 |
| 4 | SOLVENT | CMC .5 % | 8.35E-06 |
| 5 | ADVERSE_EFFECT | BBM_2_Bone Marrow Toxicity | 1.07E-06 |
| 6 | ADVERSE_EFFECT | NEU_1_Ataxia | 3.35E-06 |
| 7 | ADVERSE_EFFECT | END_2_Acute Intermittent Porphyria | 1.07E-06 |
| 8 | ADVERSE_EFFECT | KID_3_Acute Tubular Necrosis | 1.07E-06 |
| 9 | STRUCTURE_ACTIVITY | NSAID, COX-3, antipyrine like | 1.07E-06 |
| 10 | STRUCTURE_ACTIVITY | Estrogen antagonist, aromatase inhibitor * | 6.99E-07 |

* DE-71 has been shown to alter aromatase activity in number of studies 16



DrugMatrix Analysis of DE-71- Pathway Analysis







Part 2: Conclusions

- Identified 3 hepatic/non-hepatic toxicological effects of DE-71
 - Steatosis
 - Repro-related endocrine perturbations
 - Alterations in lipid homeostasis
 - Overall profile suggests DE-71 may exacerbate metabolic syndrome
- Suggestion of an AhR, CAR/PXR related MOA
- Helps focus future toxicological assessments





Acknowledgments – Iconix and Entelos

| Eser Ayanoglu | Susanne Baumhueter | Luke Birdeau | Keith A. Bostian | Lindsay Brady |
|---------------------|--------------------|--------------------|--------------------------|-----------------|
| Naiomi Breckenridge | Richard Brennan | Leslie J. Browne | John T. Calvin | Gwo-Jen Day |
| Shane Dunlea | Alan Engelberg | Barrett P. Eynon | Joe Ferng | Mark R. Fielden |
| Susan Y. Fujimoto | Brigitte Ganter | Moni Ghosh | Jeremy Gollub | Li Gong |
| Donald N. Halbert | Christopher Hu | Radha Idury | Kurt Jarnagin | Kala Jayaram |
| Michael S. B. Judo | Kyle L. Kolaja | May D. Lee | Christopher McSorley | Herb Moore |
| Ramesh V. Nair | Georges Natsoulis | Peter Nguyen | Simone M. Nicholson | David O'Reilly |
| Michael Peachey | Cecelia I. Pearson | Hang Pham | Michael M. Quach | Jacques Retief |
| Alan H. Roter | David Sciacero | Patricia Siu | Dongxu Sun | Silke Thode |
| Alexander M. Tolley | Richard Tso | Stuart Tugendreich | Antoaneta Vladimirova | Bonnie Wong |
| Jian Yang | Zhiming Zhou | | | |



Acknowledgements

- NTP/NIEHS
 - John Bucher
 - Beth Bowden
 - Jo Ann Lewis
 - Cheryl Thompson
 - Raymond Tice
 - Mary Wolfe

- SRA
 - Dan Svoboda
 - Dan Whitley
 - Tony Calore
 - Henry Norris